Kobayashi Pharmaceutical Co. is reportedly in advanced discussions for a management buyout (MBO) valued at approximately $3.2 billion (¥480 billion), with Bain Capital leading the bid. This move aims to delist the company from the Tokyo Stock Exchange. The potential buyout follows a significant crisis involving red yeast rice supplements, which has been linked to numerous deaths and has led to ongoing regulatory investigations and a substantial decline in consumer trust. The company's shares, listed on the Tokyo Stock Exchange, have faced considerable pressure since the scandal erupted in 2024.
The proposed MBO seeks to provide Kobayashi Pharmaceutical with the necessary capital and operational flexibility to restructure and recover away from the immediate scrutiny of public markets. The company has been grappling with the aftermath of the red yeast crisis, including a ¥4.1 billion ($28 million) charge in the April-June quarter for exiting the red yeast products business, and a decline in net sales by 5% year-over-year for the fiscal year ended March 2025. Operating profit margins have contracted to under 10% from 12.5% pre-crisis, largely due to recall expenses exceeding ¥10 billion and lost market share.
Regulators, including Japan's Ministry of Health, Labour and Welfare, initiated fresh investigations into Kobayashi's manufacturing processes and supply chain transparency in March 2026, two years after the initial scandal. This scrutiny followed whistleblower reports regarding inadequate testing protocols and concerns over falsified safety data submissions admitted by the company in late 2025. The crisis has seen its stock plunge, and the company's president and chairman resigned in July 2024, taking responsibility for the incident. The scandal has also led to competitors like Fancl Corp and Orihiro gaining 10-15% market share in the supplement sector.
